Elsevier

Journal of Proteomics

Volume 74, Issue 9, 24 August 2011, Pages 1735-1767
Journal of Proteomics

Review
Ending the drought: New strategies for improving the flow of affordable, effective antivenoms in Asia and Africa

https://doi.org/10.1016/j.jprot.2011.05.027Get rights and content

Abstract

The development of snake antivenoms more than a century ago should have heralded effective treatment of the scourge of snakebite envenoming in impoverished, mostly rural populations around the world. That snakebite still exists today, as a widely untreated illness that maims, kills and terrifies men, women and children in vulnerable communities, is a cruel anachronism. Antivenom can be an effective, safe and affordable treatment for snakebites, but apathy, inaction and the politicisation of public health have marginalised both the problem (making snakebite arguably the most neglected of all neglected tropical diseases) and its solution. For lack of any coordinated approach, provision of antivenoms has been pushed off the public health agenda, leading to an incongruous decline in demand for these crucial antidotes, excused and fed by new priorities, an absence of epidemiological data, and a poor regulatory framework. These factors facilitated the infiltration of poor quality products that degrade user confidence and undermine legitimate producers. The result is that tens of thousands are denied an essential life-saving medicine, allowing a toll of human suffering that is a summation of many individual catastrophes. No strategy has been developed to address this problem and to overcome the intransigence and inaction responsible for the global tragedy of snakebite. Attempts to engage with the broader public health community through the World Health Organisation (WHO), GAVI, and other agencies have failed. Consequently, the toxinology community has taken on a leadership role in a new approach, the Global Snakebite Initiative, which seeks to mobilise the resources, skills and experience of scientists and clinicians for whom venoms, toxins, antivenoms, snakes and snakebites are already fields of interest. Proteomics is one such discipline, which has embraced the potential of using venoms in bio-discovery and systems biology. The fields of venomics and antivenomics have recently evolved from this discipline, offering fresh hope for the victims of snakebites by providing an exciting insight into the complexities, nature, fundamental properties and significance of venom constituents. Such a rational approach brings with it the potential to design new immunising mixtures from which to raise potent antivenoms with wider therapeutic ranges. This addresses a major practical limitation in antivenom use recognised since the beginning of the 20th century: the restriction of therapeutic effectiveness to the specific venom immunogen used in production. Antivenomic techniques enable the interactions between venoms and antivenoms to be examined in detail, and if combined with functional assays of specific activity and followed up by clinical trials of effectiveness and safety, can be powerful tools with which to evaluate the suitability of current and new antivenoms for meeting urgent regional needs. We propose two mechanisms through which the Global Snakebite Initiative might seek to end the antivenom drought in Africa and Asia: first by establishing a multidisciplinary, multicentre, international collaboration to evaluate currently available antivenoms against the venoms of medically important snakes from specific nations in Africa and Asia using a combination of proteomic, antivenomic and WHO-endorsed preclinical assessment protocols, to provide a validated evidence base for either recommending or rejecting individual products; and secondly by bringing the power of proteomics to bear on the design of new immunising mixtures to raise Pan-African and Pan-Asian polyvalent antivenoms of improved potency and quality. These products will be subject to rigorous clinical assessment. We propose radically to change the basis upon which antivenoms are produced and supplied for the developing world. Donor funding and strategic public health alliances will be sought to make it possible not only to sustain the financial viability of antivenom production partnerships, but also to ensure that patients are relieved of the costs of antivenom so that poverty is no longer a barrier to the treatment of this important, but grossly neglected public health emergency.

Graphical abstract

An international, multidisciplinary collaboration provides a mechanism to fund evaluation of existing antivenoms and production of new antivenoms using improved antigens. This donorfunded, regulated process would deliver safe, effective free antivenoms to snakebite victims.

  1. Download : Download high-res image (96KB)
  2. Download : Download full-size image

Research highlights

► Snakebite is arguably the most neglected of all the neglected tropical diseases. ► A global shortage of accessible, safe, effective antivenoms is a major barrier to improving snakebite treatment. ► Greater deployment of proteomic, and other techniques could produce improved antivenoms. ► A multi‐disciplinary, multi‐centre collaboration to improve access to safe, effective antivenoms is proposed.

Introduction

Throughout the last decade, modern proteomic investigational tools have given toxinologists the key to revealing a dazzling array of biotoxins in the venoms of snakes, spiders, scorpions, wasps, caterpillars and a vast treasure trove of marine organisms. Never before have we been able to grasp the true complexity and diversity of venom proteins and peptides with such clarity and precision. With the aid of 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE), high-performance liquid chromatography (HPLC), a variety of sophisticated mass spectrometry platforms, and the ability to unravel protein transcriptomes or probe complex solutions with well designed ligand libraries, we have entered a new world of discovery and understanding in our quest to penetrate fundamental biological processes at the microcellular level. In these few short years we have gone beyond the limits of basic protein separation and characterisation into the very foundations of the genes that are the design blueprints of protein structure and function and the scaffolds upon which we can build treatments for diseases of many causes.

Snake venoms are rich soups of protein and peptide diversity. Many authors have discussed means of deploying proteomic investigations to unravel the venomes of numerous species [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32]. Proteomics has been used not only to explore individual species' proteomes [5], [10], [13], [16], [20], [23], [24], [29], [32], [33], [34] and sub-proteomes [19], [22], [25], [35], [36], [37], [38], but to compare and contrast differences at both intra- [17], [20], [30], [33], [39], [40] and inter-species levels [3], [9], [11], [14], [15], [17], [18], [36], [40], [41], [42], [43]. A number of excellent reviews are available [8], [44], [45], [46], [47], [48], [49], [50], [51]. Many of the recent papers have taken snake proteomics to its logical extension, antivenomics. Proteomic techniques are now being applied to the neglected field of immunotherapy for snake envenoming [8], [39], [40], [43], [47], [49], [51], [52], [53], [54], [55].This has been a most welcome development, perhaps one of the most important new avenues in antivenom research to have been explored in the post-World War II era. Whilst the origins of immunotherapy for envenoming stretch back more than 120 years, a lack of financial incentives, dwindling markets and stagnant leadership from global public health organisations have made this a field of modest improvements and very little innovation. Although antivenoms are the most effective treatment for snakebites, they are frequently inaccessible to the millions of rural poor most at risk from snakebites in low and middle-income countries [56]. This tragic reality belies the fact that, with modest investments in innovation, antivenoms are potentially one of the most cost-effective and affordable treatments [57].

As the 20th century drew to a close, the future of antivenom treatment for snakebites looked anything but certain, particularly in the developing world where these essential medicines are most needed. In Africa, where some of the most exciting developments in antivenom research have been directed, many governments, overwhelmed by the HIV/AIDS epidemic and with numerous other issues of governance to contend with, allowed many less compelling health issues to be ignored, de-prioritised or merely neglected. Snake antivenoms became scarce or non-existent as poor economic viability forced some manufacturers to leave the market, and others to downscale production [58], [59], [60]. Although an important humanitarian and social issue, death from snakebite lacks the profile, status and assistance associated with other international health crises in Africa, and reputable manufacturers have been left to carry the burden with only limited support.

Widespread shortages of antivenom in Africa opened doors to opportunists. Poorly manufactured, ineffective products and in some cases complete counterfeits emerged [59], [61], [62]. Poorly equipped National Regulatory Agencies (NRA) lack the resources and skills to detect and exclude deleterious products. Faced with the choice between an expensive but effective product or an affordable but unproven alternative, many agencies have simply opted for the latter, with disastrous results [63].

Chronic shortages of effective antivenom were not confined to Africa. In Sri Lanka, where the incidence and mortality associated with snakebites are amongst the highest in the world, dependence on poor quality, low potency antivenoms made in India resulted in many patients' not receiving effective treatment, whilst suffering adverse reaction rates as high as 80% [64], [65]. Shortages of antivenom have also become common elsewhere in Asia and Oceania, most notably in nations such as Cambodia, Laos, Malaysia and Papua New Guinea, which lack local producers. But deficiencies have also occurred in countries that do produce antivenom, such as Myanmar, where natural disasters have led to acute rises in demand [66], [67] and Viet Nam where antivenom was originally introduced by Albert Calmette in the 1890s. These inadequacies have led both to the legal sale of inappropriate products and to thriving black markets [62]. Despite initial promise and some constructive intermediate outcomes, efforts to engage the wider public health community in programmes to address these challenges have been largely unsuccessful [68]. A positive step forward was the publication, following a wide consultation process, of the WHO Guidelines for the Production, Regulation and Control of Snake Antivenom Immunoglobulins, which should be used by manufacturers and regulators for the improvement of antivenom quality [68]. However, WHO's promise to advise national producers and help them achieve prequalification of antivenoms failed to attract funding due to the Global Financial Crisis. It became apparent that the toxinology community itself must assume the responsibility for drawing international attention to the plight of snakebite victims, and developing pragmatic, lasting solutions. To this end, the Global Snakebite Initiative (GSI) was founded in collaboration with the International Society on Toxinology (IST) in 2008 [69], [70]. It is currently working towards the development of a strategic approach to improving access to antivenoms in sub-Saharan Africa and South and South-East Asia. In the 21st century, proteomics can play a vital role in the design, development and testing of antivenoms. This paper discusses some of the challenges, opportunities and practical considerations, and identifies broader issues that need to be addressed if the developing world's antivenom drought is to be ended.

Section snippets

A brief history of antivenoms

The first experimental snake antivenom was raised in pigeons against venom from a pit viper Sistrurus catenatus[71], but the pioneer of immunotherapy in the treatment of envenoming was Albert Calmette. In October 1891, whilst Calmette was foundation director of the Vaccine Institute of Viet Nam, flooding along the Mekong river led to 40 snakebites including fatalities at Bac-Liêu near the river mouth [72].The District Governor sent Calmette a barrel-full of 19 monocellate cobras (Naja kaouthia

Sub-Saharan Africa

The availability of antivenoms in Africa during the 1930s was associated with a decline in morbidity and mortality from snakebite envenoming which encouraged their widespread use. Sadly, the last 30 years have been marked by critical shortages of this life-saving medication. By 1994, it was estimated that 1.6 million vials of antivenom were required annually for the whole of Africa, yet only 100,000 vials were produced and distributed. It has been suggested that the demise of the antivenom market

How can we best contribute to sustainable improvements?

The reality of the current antivenom situations in Africa, South and South-East Asia, and Papua New Guinea is such that many obstacles stand in the path of sustainable solutions. Many of the broader issues of governance, poor medicines regulation, corruption and social inequity apply generally to the societies in which these problems have become endemic, and will perhaps take many decades to resolve. By far the most surmountable challenges are those where we can deploy considerable experience;

So what does proteomics and biotechnology have to do with all of this?

A great deal of the interest in subjecting snake venoms to rigorous proteomic investigation has its foundations in the quest to discover, characterise and harness their bioactive constituent toxins in the fields of drug discovery and design [8], [49]. But researchers have not ignored the fact that these venoms are principally diverse offensive weapons systems, and that humans are all too often the subject of their onslaughts. Many of these victims are amongst the most impoverished inhabitants

A new approach

Despite strident efforts to engage the broader public health community in seeking long-term sustainable solutions to the perennial problems facing the victims of snakebites in the developing world, success remains elusive and antivenom scarcity persists in many regions as a result of many of the factors outlined in this review. The toxinology community is now taking a much more active role in advocacy about these issues [57], [59], [62], [69], [70], [234]. Efforts are also being made to develop

Summary

This paper looks pragmatically at the problems associated with obtaining adequate supplies of safe, affordable, effective antivenoms for communities in Africa and Asia. Many of these problems are complex political, good-governance and policy-related issues that are beyond easy resolution. This review acknowledges those obstacles and considers what can and cannot be achieved. It explores in detail how some of the technological problems associated with producing effective antivenoms can and are

References (261)

  • S.C. Wagstaff et al.

    Combined snake venomics and venom gland transcriptomic analysis of the ocellated carpet viper, Echis ocellatus

    J Proteomics

    (2009)
  • E. Fasoli et al.

    Exploring the venom proteome of the African puff adder, Bitis arietans, using a combinatorial peptide ligand library approach at different pHs

    J Proteomics

    (2010)
  • R.B. Currier et al.

    Intra-specific variation in venom of the African Puff Adder (Bitis arietans): differential expression and activity of snake venom metalloproteinases (SVMPs)

    Toxicon

    (2010)
  • V. Guimarães‐Gomes et al.

    Cloning, characterization, and structural analysis of a C-type lectin from Bothrops insularis (BiL) venom

    Arch Biochem Biophys

    (2004)
  • I.H. Tsai et al.

    Comparative proteomics and subtyping of venom phospholipases A2 and disintegrins of Protobothrops pit vipers

    Biochim Biophys Acta

    (2004)
  • A.L. Oliveira-Carvalho et al.

    Identification and characterization of a new member of snake venom thrombin inhibitors from Bothrops insularis using a proteomic approach

    Toxicon

    (2008)
  • M.Z. Sun et al.

    A novel phospholipase A2 from Agkistrodon blomhoffii ussurensis venom: purification, proteomic, functional and structural characterizations

    Biochimie

    (2009)
  • V. Nunez et al.

    Snake venomics and antivenomics of Bothrops atrox venoms from Colombia and the Amazon regions of Brazil, Peru and Ecuador suggest the occurrence of geographic variation of venom phenotype by a trend towards paedomorphism

    J Proteomics

    (2009)
  • J. Boldrini-Franca et al.

    Snake venomics and antivenomics of Crotalus durissus subspecies from Brazil: assessment of geographic variation and its implication on snakebite management

    J Proteomics

    (2010)
  • J.M. Gutierrez et al.

    Snake venomics and antivenomics: proteomic tools in the design and control of antivenoms for the treatment of snakebite envenoming

    J Proteomics

    (2009)
  • J.W. Fox et al.

    Timeline of key events in snake venom metalloproteinase research

    J Proteomics

    (2009)
  • J.J. Calvete et al.

    Venoms, venomics, antivenomics

    FEBS Lett

    (2009)
  • P.G. Righetti et al.

    Plucking, pillaging and plundering proteomes with combinatorial peptide ligand libraries

    J Chromatogr A

    (2010)
  • J.J. Calvete

    Antivenomics and venom phenotyping: a marriage of convenience to address the performance and range of clinical use of antivenoms

    Toxicon

    (2010)
  • J.J. Calvete et al.

    Snake venomics and antivenomics of Bothrops colombiensis, a medically important pitviper of the Bothrops atrox–asper complex endemic to Venezuela: contributing to its taxonomy and snakebite management

    J Proteomics

    (2009)
  • G.P. Espino-Solis et al.

    Antidotes against venomous animals: state of the art and prospectives

    J Proteomics

    (2009)
  • C. Correa-Netto et al.

    Immunome and venome of Bothrops jararacussu: a proteomic approach to study the molecular immunology of snake toxins

    Toxicon

    (2010)
  • N. Brown et al.

    Antivenom: the most cost-effective treatment in the world?

    Toxicon

    (2010)
  • R.D. Theakston et al.

    Crisis in snake antivenom supply for Africa

    Lancet

    (2000)
  • R.D. Theakston et al.

    Report of a WHO workshop on the standardization and control of antivenoms

    Toxicon

    (2003)
  • D.A. Warrell

    Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product—‘what's in a name?’

    Trans R Soc Trop Med Hyg

    (2008)
  • C.A. Ariaratnam et al.

    An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii)

    Trans R Soc Trop Med Hyg

    (2001)
  • D.J. Williams et al.

    The Global Snake Bite Initiative: an antidote for snake bite

    Lancet

    (2010)
  • J.M. Gutierrez et al.

    Snakebite envenoming from a global perspective: towards an integrated approach

    Toxicon

    (2010)
  • B.J. Hawgood

    Doctor Albert Calmette 1863–1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination

    Toxicon

    (1999)
  • B.J. Hawgood

    Pioneers of anti-venomous serotherapy: Dr Vital Brazil (1865–1950)

    Toxicon

    (1992)
  • K.D. Winkel et al.

    Twentieth century toxinology and antivenom development in Australia

    Toxicon

    (2006)
  • B.J. Hawgood

    Poul Agerholm Christensen MD (1912–1991): antivenom production at the South African Institute for Medical Research

    Toxicon

    (2001)
  • A. Coulter et al.

    Simplified preparation of rabbit Fab fragments

    J Immunol Methods

    (1983)
  • D.C. Smith et al.

    An affinity purified ovine antivenom for the treatment of Vipera berus envenoming

    Toxicon

    (1992)
  • S.A. Seifert et al.

    Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies

    Ann Emerg Med

    (2001)
  • J.F. Morais et al.

    Snake antivenoms from hyperimmunized horses: comparison of the antivenom activity and biological properties of their whole IgG and F(ab′)2 fragments

    Toxicon

    (1994)
  • M.C. dos_Santos et al.

    Purification of F(ab′)2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield

    Toxicon

    (1989)
  • G. Rojas et al.

    Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production

    Toxicon

    (1994)
  • T. Burnouf et al.

    Assessment of the viral safety of antivenoms fractionated from equine plasma

    Biologicals

    (2004)
  • J.P. Chippaux et al.

    Clinical safety of a polyvalent F(ab′)2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators

    Trans R Soc Trop Med Hyg

    (1998)
  • J. Nawarak et al.

    Proteomics of snake venoms from Elapidae and Viperidae families by multidimensional chromatographic methods

    Electrophoresis

    (2003)
  • S. Li et al.

    Proteomic characterization of two snake venoms: Naja naja atra and Agkistrodon halys

    Biochem J

    (2004)
  • A. Bazaa et al.

    Snake venomics: comparative analysis of the venom proteomes of the Tunisian snakes Cerastes cerastes, Cerastes vipera and Macrovipera lebetina

    Proteomics

    (2005)
  • S.M. Serrano et al.

    A multifaceted analysis of viperid snake venoms by two-dimensional gel electrophoresis: an approach to understanding venom proteomics

    Proteomics

    (2005)
  • Cited by (193)

    View all citing articles on Scopus
    View full text